Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
By P. Major, A. Lortholary, J. Hon, E. Abdi, Gordon B. Mills, H. Menssen, F. Yunus, R. Bell, J. Body, E. Quebe‐Fehling and 1 more. Journal of Clinical Oncology, 2001
745 citations recorded by the source corpus.
Subfields: Nephrology, Oncology, Orthopedics and Sports Medicine
View Paper: https://www.semanticscholar.org/paper/c6371efa14c9f90e91e3373e52cbbcfb7cde8b42
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. (2003, methodology): “Zoledronic acid (ZOMETA; Novartis Pharma AG, Basel, Switzerland/Novartis Pharmaceuticals Corporation, East Hanover, NJ) is a new, highly potent, nitrogen-containing bisphosphonate that has demonstrated superior efficacy for the treatment of HCM compared with pamidronate, the current standard treatme”
- Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma (2003, background): “The specifications for diagnosing each of these events were described previously.23 For the primary efficacy analysis, HCM was not included in the definition of SREs, because zoledronic acid already has demonstrated efficacy in treating HCM.24 However, HCM is a clinically important event that can be”
- American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. (2009, background): “The clinical efficacy of IV bisphosphonates for the reatment of hypercalcemia and bone metastases is ell established.(2-5) IV bisphosphonate exposure in he setting of managing malignancy remains the major isk factor for BRONJ.”
- Hypercalcemia Associated with Cancer (2005, background): “Direct comparison of sustained infusion of human parathyroid hormone-related protein(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers.”